PreOmics, Biognosys announces ‘favorable’ outcome in U.S. patent challenge

PreOmics and Biognosys announced a favorable outcome in an inter partes review proceeding IPR2024-01473 before the U.S. Patent Trial and Appeal Board. The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Women’s Hospital, and exclusively licensed to Seer, Inc. The USPTO struck down the sole independent claim of the ‘360 patent, among other claims. The PTAB specifically invalidated Claim 1, which attempted to cover workflows using multiple nanoparticle types to form biomolecule coronas and detect proteins across a wide dynamic range. “This outcome confirms what we have consistently believed from the outset: the fundamental concepts at issue were already known in the scientific literature,” said Dr. Oliver Rinner, co-founder and managing director of Biognosys. “We welcome the PTAB’s thorough evaluation and we are very pleased with this clear result.”